Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Respirics Inc.
This is a single blind (investigator unblinded), open label, single exposure, non-randomized, single center, outpatient, stepwise, rising dose study in male subjects with mild intermittent asthma to assess topical safety and tolerability of Albuterol Sulfate Acu-30™ DPI, compared with Placebo Acu-30™ DPI. Increasing doses of each drug will be administered in a sequential fashion in 4 steps to 3 different subjects at each step (a total of 12 subjects) with mild intermittent asthma in each step.
Medically normal subjects with no significant abnormal findings
No tobacco (nicotine products) use for at least 2 years before the study starts
Normal (or abnormal and clinically insignificant) laboratory values at screening (potassium or glucose levels)
No significant medical or surgical conditions (COPD, cystic fibrosis, severe allergic rhinitis)
You may not be if
Past or present history of experiencing any allergic reaction to the medications/formulations administered in this study, or in the opinion of the Principal Investigator, suggests an increased potential for an adverse hypersensitivity
Subject with abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Principal Investigator